Cardio-Oncology Midwest Regional Symposium

癌症患者/幸存者的心血管护理范例- 肿瘤学中西部地区教育研讨会 摘要 在美国仅次于心血管疾病（CVD），癌症仍然是导致死亡的主要原因 世界上尽管如此，癌症的总体死亡率已经下降， 由于肿瘤治疗的进步，癌症幸存者增加了， 提供者注意预防和监测不良后果。到2030年1月1日， 据估计，癌症幸存者的人口将增加到2210多万， 人口的增长和老龄化。 心血管疾病是癌症幸存者发病和死亡的主要原因， 是15至39岁癌症幸存者死亡的主要原因。许多 癌症的治疗方法显著增加了心肌病，局部缺血， 心血管事件（包括心肌梗死和室性心律失常），以及 高血压 肿瘤学是一个新兴领域，重点是预防不良心血管结局 活动性癌症患者，改善癌症患者的整体心血管健康 幸存者这涉及到对癌症和癌症之间相互作用的具体理解。 心血管系统;以及癌症治疗剂的内在知识，包括 化疗、放疗和更新的靶向治疗/免疫治疗。领域 随着癌症治疗的不断变化，心脏肿瘤学变得更加专业化; 强调了教育和保持临床医生与时俱进的巨大需求。这一点尤其重要 对于初级医生和其他护理人员，他们仍然参与日常护理， 癌症患者;并且需要认识或了解所接受的癌症治疗，短期和 长期副作用和管理策略。 我们提出了一个教育活动，将提供最新的临床更新的治疗， 在肿瘤学环境中的心血管疾病。本计划的目的是熟悉 初级保健提供者、住院医生、肿瘤学家、心脏病学家、高级实践提供者， 药剂师和受训人员，了解癌症患者心脏病的最新治疗方法/ 幸存者;以及确定正在进行的研究，以进一步提高我们对癌症的理解 治疗相关的心血管功能障碍，以进一步加强管理策略， 未来鉴于美国许多地区缺乏心脏肿瘤专家，程序 将武装全科医生与实用的工具，以促进预防和治疗 CVD作为癌症治疗的结果，帮助他们的癌症患者活得更长，更健康。

Paradigms in Cardiovascular Care of the Cancer Patient/Survivor – Biennial Cardio- Oncology Midwest Regional Educational Symposium Abstract Second to cardiovascular disease (CVD) in the U.S., cancer remains the leading cause of death in the world. Nonetheless, the overall death rate from cancer has declined, and the number of cancer survivors has increased as a result of advancements in oncologic treatment, and greater attention by providers to prevention and surveillance for adverse outcomes. By January 1, 2030, it is estimated that the population of cancer survivors will increase to more than 22.1 million due to the growth and aging of the population alone. CVD is the major cause of morbidity and mortality among cancer survivors, and is considered to be a major cause of mortality among cancer survivors aged 15 to 39 years old. Many therapeutic approaches to cancer significantly increase the risk of cardiomyopathy, ischemia, cardiovascular events (including myocardial infarction and ventricular arrhythmias), and hypertension. Cardio-oncology is a nascent field that focuses on preventing adverse cardiovascular outcomes in patients with active cancer and improving the overall cardiovascular health of cancer survivors. This involves specific understanding of interactions between cancer and the cardiovascular system; as well as intrinsic knowledge of cancer therapeutic agents including chemotherapy, radiation therapy, and newer targeted therapies/immunotherapy. The field of cardio-oncology is becoming more specialized with constant variations in cancer treatment; and emphasizes a great need to educate and keep clinician up to date. This is particularly important for primary doctors and other caregivers that remain peripherally involved in routine care of cancer patient; and need to be cognizant or aware of cancer therapy(ies) received, short and long-term side effects, and management strategies. We propose an educational activity that will provide the latest clinical updates in the treatment of cardiovascular conditions in an oncology setting. The purpose of this program is to familiarize primary care providers, hospitalists, oncologists, cardiologists, advanced practice providers, pharmacists, and trainees, with updated treatment of cardiac conditions seen in cancer patients/ survivors; as well as identify ongoing research to further improve our understanding of cancer therapy-related cardiovascular dysfunction to further enhance management strategies for the future. Given the paucity of cardio-oncology specialists in many parts of the U.S., the program will arm general practitioners with practical tools to promote the prevention and treatment of CVD as a result of cancer therapy, to help their cancer patients live longer and healthier lives.